Commerzbank Aktiengesellschaft Vertex Pharmaceuticals Inc Transaction History

Commerzbank Aktiengesellschaft

$3.75 Billion
Q3 2024

A detailed history of Commerzbank Aktiengesellschaft transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Commerzbank Aktiengesellschaft holds 1,272 shares of VRTX stock, worth $516,126. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,272

Previous 858 48.25%

Holding current value

$516,126

Previous $403,000 46.9%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 22, 2024	BUY	$460.0 - $505.78 $190,440 - $209,392	414 Added 48.25%	1,272 $592,000
Q2 2024 Jul 22, 2024	BUY	$392.81 - $485.53 $27,889 - $34,472	71 Added 9.02%	858 $403,000
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $11,415 - $12,490	28 Added 3.69%	787 $329,000
Q4 2023 Sep 30, 2024	SELL	$343.0 - $410.68 $33,957 - $40,657	-99 Reduced 11.54%	759 $309,000
Q4 2023 Feb 01, 2024	BUY	$343.0 - $410.68 $260,337 - $311,706	759 New	759 $309,000
Q2 2020 Jul 21, 2020	SELL	$225.48 - $295.8 $1.25 Million - $1.64 Million	-5,548 Closed	0 $0
Q1 2020 Oct 03, 2024	BUY	$199.77 - $247.81 $936,921 - $1.16 Million	4,690 Added 546.62%	5,548 $1.32 Million
Q1 2020 Apr 29, 2020	SELL	$199.77 - $247.81 $6.05 Million - $7.5 Million	-30,271 Reduced 84.51%	5,548 $1.32 Million
Q4 2019 Oct 03, 2024	BUY	$166.71 - $223.91 $5.83 Million - $7.83 Million	34,961 Added 4074.71%	35,819 $7.84 Million
Q4 2019 Jan 17, 2020	SELL	$166.71 - $223.91 $28.8 Million - $38.6 Million	-172,501 Reduced 82.81%	35,819 $7.84 Million
Q3 2019 Oct 03, 2024	BUY	$166.23 - $187.09 $34.5 Million - $38.8 Million	207,462 Added 24179.72%	208,320 $35.3 Million
Q3 2019 Oct 17, 2019	SELL	$166.23 - $187.09 $146,947 - $165,387	-884 Reduced 0.42%	208,320 $35.3 Million
Q2 2019 Oct 03, 2024	BUY	$164.61 - $190.37 $34.3 Million - $39.7 Million	208,346 Added 24282.75%	209,204 $38.4 Million
Q2 2019 Jul 23, 2019	SELL	$164.61 - $190.37 $8.14 Million - $9.41 Million	-49,455 Reduced 19.12%	209,204 $38.4 Million
Q1 2019 Oct 03, 2024	BUY	$163.73 - $194.7 $42.2 Million - $50.2 Million	257,801 Added 30046.74%	258,659 $47.6 Million
Q1 2019 May 13, 2019	SELL	$163.73 - $194.7 $2.62 Million - $3.12 Million	-16,017 Reduced 5.83%	258,659 $47.6 Million
Q4 2018 Oct 03, 2024	BUY	$151.91 - $192.21 $41.6 Million - $52.6 Million	273,818 Added 31913.52%	274,676 $45.5 Million
Q4 2018 Feb 06, 2019	BUY	$151.91 - $192.21 $370,204 - $468,415	2,437 Added 0.9%	274,676 $45.5 Million
Q3 2018 Oct 04, 2024	BUY	$167.73 - $192.74 $45.5 Million - $52.3 Million	271,381 Added 31629.49%	272,239 $52.5 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $1.5 Million - $1.72 Million	8,946 Added 3.4%	272,239 $52.5 Million
Q2 2018 Oct 04, 2024	BUY	$145.72 - $169.96 $38.2 Million - $44.6 Million	262,435 Added 30586.83%	263,293 $44.7 Million
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $272,787 - $318,165	1,872 Added 0.72%	263,293 $44.7 Million
Q1 2018 Oct 04, 2024	BUY	$151.6 - $177.13 $615,950 - $719,679	4,063 Added 1.58%	261,421 $42.6 Million
Q1 2018 May 01, 2018	BUY	$151.6 - $177.13 $615,950 - $719,679	4,063 Added 1.58%	261,421 $42.6 Million
Q4 2017 Oct 04, 2024	BUY	$137.28 - $155.55 $35.2 Million - $39.9 Million	256,500 Added 29895.1%	257,358 $38.6 Million
Q4 2017 Jan 26, 2018	BUY	$137.28 - $155.55 $5.55 Million - $6.28 Million	40,401 Added 18.62%	257,358 $38.6 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $839,156 - $919,089	5,665 Added 2.68%	216,957 $33 Million
Q2 2017 Aug 09, 2017	BUY	N/A	211,292	211,292 $27.2 Million

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $104B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

News

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.

Account

Commerzbank Aktiengesellschaft Vertex Pharmaceuticals Inc Transaction History